Genmab — Juli 2020
-
Jan går ikke på pension før Genmab er blevet et ikonisk biotekselskab
-
a bit surprised that this Nivolumab/ Daratumumab trial in Lung / Breast cancer is extending Study Completion date by a year. Makes me wonder how many they actually recruited and still have benefit https://clinicaltrials.gov/ct2/history/NCT03098550?A=29&B=30&C=merged#StudyPageTop
-
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Blenrep (belantamab mafodotin) to treat adult patients with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, a proteasome inhibitor and a CD-38 monoclonal antibody. https://www.ema.europa.eu/en/news/first-antibody-drug-conjugate-multiple-myeloma-patients-limited-treatment-options
-
Det strømmer ikke ligefrem med større købere på nogen niveauer i dag.
-
NBI: -2,42%
-
Er der mere nyt om Trump´s plan for at sænke medicinpriser i US. Udkastet skulle komme i dag.
-
Dutch healthcare institute expects Teprotumumab to be filed in 2020 in EMA https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/teprotumumab-chronische-immuunziekten-chronische-immuunziekten-overig/versie4
-
Vi kunne godt bruge noget positivt...storm efter stilhed;-)
-
Jeps..nohope..vi må tage til takke med de små glæder..:-)
-
inden det begynder at storme;-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind